Extramural Support Reimbursement of Travel and Subsistence Expenses Toward Living Organ Donation Program, 873-875 [E9-31312]
Download as PDF
Federal Register / Vol. 75, No. 3 / Wednesday, January 6, 2010 / Notices
873
TRANSACTION GRANTED EARLY TERMINATION—Continued
ET date
Trans. No.
ET req
status
Party name
G
G
20100177
G
G
G
Odyssey Investment Partners Fund IV, L.P.
TA IX L.P.
One Call Medical, Inc.
G
G
G
Excellere Capital Fund, L.P.
Med Tech Holdings, Inc.
Med Tech College, L.L.C.
G
G
G
Mitsui Sumitomo Insurance Group Holdings, Inc.
Aioi Insurance Company, Limited.
Aioi Insurance Company, Limited.
20100226
G
G
G
Odyssey Investment Partners Fund IV, L.P.
New S Corp. I, Inc.
Wencor Holdings LLC.
20100230
G
G
G
JPMorgan Chase & Co.
HTS Stiftung.
Constantia Packaging AG.
20100232
G
G
G
Trow Global Holdings Inc.
Ivan Dvorak.
Teng & Associates, Inc.
20100233
G
G
G
Carl C. Icahn.
Tropicana Entertainment Inc.
Tropicana Entertainment Inc.
20100235
G
G
G
G
H.I.G Capital Partners IV, LP.
Tennessee Valley Ventures, L.P.
Food Holdings, Inc.
Southern Quality Meats, Inc.
20100236
G
G
G
People’s United Financial, Inc.
Financial Federal Corporation.
Financial Federal Corporation.
20100238
G
G
G
G
Berkshire Hathaway Inc.
American Electric Power Company, Inc.
AEP Texas Central Company.
AEP Texas North Company.
20100242
jlentini on DSKJ8SOYB1PROD with NOTICES
TeleCommunication Systems, Inc.
Networks in Motion, Inc.
Networks in Motion, Inc.
20100225
By Direction of the Commission.
G
G
G
20100219
Donald S. Clark,
Secretary.
[FR Doc. E9–31207 Filed 1–5–10; 8:45 am]
The Edward W. Scripps Trust.
TCM Parent, LLC.
TCM Parent, LLC.
20100218
FOR FURTHER INFORMATION CONTACT:
Sandra M. Peay, Contact Representative
or Renee Hallman, Contact
Representative, Federal Trade
Commission, Premerger Notification
Office, Bureau of Competition, Room H–
303, Washington, DC 20580, (202) 326–
3100.
G
G
G
20100210
11–DEC–09 ..............................................................
Northrop Grumman Corporation.
TASC, Inc.
G
G
G
The Procter & Gamble Company.
MDVIP, Inc.
MDVIP, Inc.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Extramural Support Reimbursement of
Travel and Subsistence Expenses
Toward Living Organ Donation
Program
AGENCY: Health Resources and Services
Administration, HHS.
ACTION: Request for Information.
BILLING CODE 6750–01–M
SUMMARY: Congress has provided
specific authority under section 377 of
the Public Health Service (PHS) Act, 42
VerDate Nov<24>2008
16:28 Jan 05, 2010
Jkt 220001
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
U.S.C. 274f, as amended by Public Law
108–216 for providing reimbursement of
travel and subsistence expenses for
certain individuals donating their
organs. Additionally, Congress
authorized the Secretary to provide
reimbursement for other incidental nonmedical expenses as the Secretary
determines by regulation to be
appropriate.
Accordingly, under the existing
Program launched in October 2007,
individuals who meet Program
eligibility guidelines may receive
reimbursement for qualifying travel and
subsistence expenses related to live
organ donation. The existing Program
E:\FR\FM\06JAN1.SGM
06JAN1
jlentini on DSKJ8SOYB1PROD with NOTICES
874
Federal Register / Vol. 75, No. 3 / Wednesday, January 6, 2010 / Notices
structure is based on Section 377(a)(1)
of the PHS Act. This section explicitly
allows the Secretary to provide
reimbursement of travel and subsistence
expenses incurred by living organ
donors. HRSA wishes to implement
Section 377(a)(2) of the PHS Act which
authorizes the Secretary to issue
regulations describing other incidental
nonmedical expenses appropriate for
reimbursement under this Program. The
Department is considering initiating
rulemaking proposing that
reimbursement be extended to
additional expenses incurred by living
donors as ‘‘incidental nonmedical
expenses’’ under 42 U.S.C. 274f(a)(2).
Before initiating such rulemaking,
HRSA is soliciting input from the
community on specific incidental
nonmedical expenses to be considered
for reimbursement. HRSA is looking for
guidance from the community on the
mechanism(s) to determine the
appropriate reimbursement amount for
these additional expenses and to
validate that donors incurred or will
incur these additional expenses as a
result of making living donations of
their organs. For example, if the
community thinks lost wages and
childcare expenses are incidental
nonmedical expenses the Program
should consider for reimbursement,
how much the Program should
reimburse donors for these expenses
and on what basis should this
determination be made?
Individuals can send their comments
either by mail, fax, or email to the
Division of Transplantation at the
address listed below. In addition, the
Division plans to sponsor three
conference calls to discuss the Program.
DATES: To be considered, written
comments must be postmarked no later
than March 22, 2010. The conference
calls will be held on Tuesday, February
23, 2010 from 10 a.m. to 11:30 a.m.;
Wednesday, February 24, 2010 from
2:30 p.m. to 4 p.m.; and Friday, March
5, 2010 from 1 p.m. to 2:30 p.m. All
listed times are eastern standard times.
Participants must register for the
conference calls by contacting Richard
Laeng, Public Health Analyst, at (301)
443–5410 or e-mail rlaeng@hrsa.gov.
The registration deadline is Thursday,
February 18, 2010. Because the same
information will be discussed on all the
calls, it is not necessary to register for
multiple calls. Registration is not
guaranteed; it is on a first come basis.
ADDRESSES: Please send all written
comments to Mesmin Germain, Public
Health Analyst, Division of
Transplantation, Healthcare Systems
Bureau, Health Resources and Services
VerDate Nov<24>2008
16:28 Jan 05, 2010
Jkt 220001
Administration, Department of Health
and Human Services, Room 12C–06,
Parklawn Building, 5600 Fishers Lane,
Rockville, Maryland 20857; telephone:
(301) 443–0053; fax: (301) 594–6095; email: mgermain@hrsa.gov.
FOR FURTHER INFORMATION CONTACT:
Mesmin Germain, Public Health
Analyst, Division of Transplantation,
Healthcare Systems Bureau, Health
Resources and Services Administration,
Department of Health and Human
Services, Room 12C–06, Parklawn
Building, 5600 Fishers Lane, Rockville,
Maryland 20857; telephone: (301) 443–
0053; fax: (301) 594–6095; e-mail:
mgermain@hrsa.gov.
SUPPLEMENTARY INFORMATION:
Background
On September 14, 2006, HRSA
awarded a 4-year cooperative agreement
to the Regents of the University of
Michigan to establish a national
Program to provide reimbursement to
living donors for travel and subsistence
expenses, as well as additional expenses
authorized by any future regulations
issued by the Secretary. The Regents of
the University of Michigan in
partnership with the American Society
of Transplant Surgeons (ASTS)
established the National Living Donor
Assistance Center (NLDAC) to operate
this national Program.
On October 17, 2007, The Regents of
the University of Michigan and ASTS
officially launched NLDAC. NLDAC is
located at the ASTS Headquarter in
Arlington, Virginia. NLDAC has
officially partnered with 299 living
transplant programs throughout the
United States to submit applications for
reimbursement on behalf of their living
donors. Applications are filed through
the transplant centers and reviewed by
a committee at NLDAC. Program
eligibility is based on donor and
recipient incomes of 300 percent or less
of the HHS Poverty Guidelines.
Applicants who do not meet eligibility
guidelines may request a waiver. All
waiver requests are reviewed for
approval by HRSA. The Program
provides prospective reimbursement to
living donors based on the estimated
travel expenses related to the donation
process. Funds are provided through a
controlled value card, giving NLDAC
the ability to add and subtract funds as
needed. All expenses are monitored in
real time by NLDAC to ensure that
donors are using funds according to
Program guidelines.
HRSA sought input from the public
from the conceptual stage of the
Program through the determination of
the Program’s final eligibility criteria to
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
ensure that the Program addresses the
needs of the public:
• On October 13, 2005, HRSA
published a Request for Public
Comments on the proposed Program to
provide reimbursement of travel and
subsistence expenses in the Federal
Register (70 FR 59760).
• On April 9, 2007, HRSA published
a Request for Public Comments
concerning the proposed Program
eligibility criteria in the Federal
Register (72 FR 17564).
• On October 5, 2007, HRSA
published a Response to Solicitation of
Comments and Final Program Eligibility
Guidelines in the Federal Register (72
FR 57049).
• On March 5, 2008, HRSA published
a Request for Public Comments on
proposed changes to the reimbursement
of travel and subsistence expenses
Program eligibility criteria (concerning
additional follow-up visits for donors)
in the Federal Register (73 FR 11930).
• On June 20, 2008, HRSA published
a change to Program eligibility
guidelines to provide reimbursement for
additional follow-up visits for donors in
the Federal Register (73 FR 35143).
• On March 4, 2009, HRSA published
a Request for Public Comments on a
proposed change to the Program
eligibility criteria (concerning the
follow-up period) in the Federal
Register (74 FR 9407).
• On June 19, 2009, HRSA published
an amendment to Program eligibility
guidelines to extend follow-up period
that donors may receive reimbursement
for qualifying expenses in the Federal
Register (74 FR 29218).
Through September 30, 2009, the
Program has facilitated 370 living organ
transplants. Overall, 697 applications
have been approved for funding under
the established Program eligibility
guidelines. The average reimbursement
per living donor is approximately
$2,600.
HRSA initiated this Program to
address the travel and subsistence
expenses faced by potential donors,
recipients, and family alike. Even with
this support, living donors still face
other financial barriers related to the
donation process.
Reimbursement of other incidental
nonmedical expenses being considered
would further diminish the financial
barriers faced by many donors.
Reimbursement for the additional
expenses would be provided while
maintaining the existing Program
guidelines, including capping total
reimbursement per donor and
companions at $6,000. The expansion
will be provided under the Qualified
E:\FR\FM\06JAN1.SGM
06JAN1
Federal Register / Vol. 75, No. 3 / Wednesday, January 6, 2010 / Notices
Expenses Section of the Program
Eligibility Guidelines.
Any payment permitted under this
authority must not violate section 301 of
the National Organ Transplant Act of
1984, which makes it ‘‘unlawful for any
person to knowingly acquire, receive, or
otherwise transfer any human organ for
valuable consideration for use in human
transplantation if the transfer affects
interstate commerce.’’ 42 U.S.C. 274e(a).
Certain expenses are excluded from the
scope of valuable consideration,
including ‘‘expenses of travel, housing,
and lost wages incurred by the donor of
a human organ in connection with the
donation of the organ.’’ 42 U.S.C.
274e(c)(2). As the Secretary considers
rulemaking, she will consider this
criminal prohibition in evaluating
which expenses are appropriate for
reimbursement under this Program.
HRSA is seeking public comment as
to whether the Secretary should initiate
rulemaking to allow reimbursement
under this Program for specific
incidental nonmedical expenses and
concerning which incidental
nonmedical expenses should be
included in such rulemaking.
Dated: December 29, 2009.
Mary K. Wakefield,
Administrator.
[FR Doc. E9–31312 Filed 1–5–10; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–D–0525]
Guidance for Industry on New Contrast
Imaging Indication Considerations for
Devices and Approved Drug and
Biological Products; Availability
AGENCY:
Food and Drug Administration,
HHS.
jlentini on DSKJ8SOYB1PROD with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a guidance for industry
entitled ‘‘New Contrast Imaging
Indication Considerations for Devices
and Approved Drug and Biological
Products,’’ dated December 2009. As
part of the Medical Device User Fee
Amendments of 2007 (MDUFA)
Commitment for the Performance Goals
and Procedures commitment letter, FDA
agreed to publish guidance for medical
imaging devices for use with imaging
contrast agents or radiopharmaceuticals.
FDA intends this guidance to assist
developers of medical imaging devices
VerDate Nov<24>2008
16:28 Jan 05, 2010
Jkt 220001
and imaging drug/biological products
that provide image contrast
enhancement. The final guidance
announced in this document fulfills
FDA’s commitment to issue guidance
called for by the commitment letter. The
guidance supercedes the draft guidance
of the same title dated September 30,
2008.
DATES: Submit written or electronic
comments on agency guidances at any
time.
ADDRESSES: Submit written requests for
single copies of this guidance to the
Division of Drug Information, Center for
Drug Evaluation and Research, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, rm. 2201,
Silver Spring, MD 20993–0002. Send
one self-addressed adhesive label to
assist that office in processing your
requests. Submit written comments on
the guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the guidance
document.
FOR FURTHER INFORMATION CONTACT:
Patricia Y. Love, Office of Combination
Products (HFG–3), Office of the
Commissioner, Food and Drug
Administration, 15800 Crabbs Branch
Way, Rockville, MD 20855, 301–427–
1934.
SUPPLEMENTARY INFORMATION:
I. Background
As part of the Medical Device User
Fee Amendments of 2007 (MDUFA)
Commitment for the Performance Goals
and Procedures, Item I.N of the
September 27, 2007, commitment letter,
FDA agreed to publish draft guidance by
September 30, 2008, for medical
imaging devices for use with imaging
contrast agents or radiopharmaceuticals.
Further, the agreement stated that the
‘‘draft guidance will be published by the
end of FY 2008, and will be subject to
a 90-day comment period. FDA will
issue a final guidance within one year
of the close of the public comment
period.’’ The draft guidance was dated
September 30, 2008 (73 FR 58604,
October 7, 2008); the comment period
closed on January 5, 2009. FDA held
meetings with imaging industry
stakeholders in July 2008 and August
2009. The final guidance announced in
this document fulfills FDA’s
commitment to issue final guidance
called for by the commitment letter. The
guidance supercedes the draft guidance
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
875
of the same title dated September 30,
2008.
FDA is announcing the availability of
guidance for industry entitled ‘‘New
Contrast Imaging Indication
Considerations for Devices and
Approved Drug and Biological
Products.’’ FDA intends this guidance to
assist developers of medical imaging
devices and imaging drug/biological
products that provide image contrast
enhancement. Particularly, this
guidance focuses on the following
topics: (1) When the imaging device
developers may add certain new
imaging contrast indications to their
device for use with already approved
imaging drugs without a need for a
modification of the drug labeling, (2)
when the imaging drug developers may
add certain new imaging contrast
indications to their drug for use with
already approved imaging devices
without a need for a modification of the
device labeling, and (3) what type of
marketing submission(s) imaging drug
or imaging device developers should
submit to FDA to request approval/
clearance to add a new imaging contrast
indication. FDA intends for the
recommendations in this guidance to
promote timely and effective review of,
and consistent and appropriate
regulation and labeling for imaging
drugs and devices.
FDA notes that during the comment
period, certain topics identified in the
docket were beyond the scope of the
guidance document. These comments
included requests for guidance on
developing specific medical imaging
indications (e.g., myocardial perfusion
or breast cancer imaging) and offered
suggestions for the type of acceptable
data. FDA will consider whether
separate guidance would be appropriate.
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the agency’s
current thinking on ‘‘New Contrast
Imaging Indication Considerations for
Devices and Approved Drug and
Biological Products’’. It does not create
or confer any rights for or on any person
and does not operate to bind FDA or the
public. An alternative approach may be
used if such approach satisfies the
requirements of the applicable statutes
and regulations.
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
21 CFR 807 have been approved under
E:\FR\FM\06JAN1.SGM
06JAN1
Agencies
[Federal Register Volume 75, Number 3 (Wednesday, January 6, 2010)]
[Notices]
[Pages 873-875]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-31312]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Extramural Support Reimbursement of Travel and Subsistence
Expenses Toward Living Organ Donation Program
AGENCY: Health Resources and Services Administration, HHS.
ACTION: Request for Information.
-----------------------------------------------------------------------
SUMMARY: Congress has provided specific authority under section 377 of
the Public Health Service (PHS) Act, 42 U.S.C. 274f, as amended by
Public Law 108-216 for providing reimbursement of travel and
subsistence expenses for certain individuals donating their organs.
Additionally, Congress authorized the Secretary to provide
reimbursement for other incidental non-medical expenses as the
Secretary determines by regulation to be appropriate.
Accordingly, under the existing Program launched in October 2007,
individuals who meet Program eligibility guidelines may receive
reimbursement for qualifying travel and subsistence expenses related to
live organ donation. The existing Program
[[Page 874]]
structure is based on Section 377(a)(1) of the PHS Act. This section
explicitly allows the Secretary to provide reimbursement of travel and
subsistence expenses incurred by living organ donors. HRSA wishes to
implement Section 377(a)(2) of the PHS Act which authorizes the
Secretary to issue regulations describing other incidental nonmedical
expenses appropriate for reimbursement under this Program. The
Department is considering initiating rulemaking proposing that
reimbursement be extended to additional expenses incurred by living
donors as ``incidental nonmedical expenses'' under 42 U.S.C.
274f(a)(2).
Before initiating such rulemaking, HRSA is soliciting input from
the community on specific incidental nonmedical expenses to be
considered for reimbursement. HRSA is looking for guidance from the
community on the mechanism(s) to determine the appropriate
reimbursement amount for these additional expenses and to validate that
donors incurred or will incur these additional expenses as a result of
making living donations of their organs. For example, if the community
thinks lost wages and childcare expenses are incidental nonmedical
expenses the Program should consider for reimbursement, how much the
Program should reimburse donors for these expenses and on what basis
should this determination be made?
Individuals can send their comments either by mail, fax, or email
to the Division of Transplantation at the address listed below. In
addition, the Division plans to sponsor three conference calls to
discuss the Program.
DATES: To be considered, written comments must be postmarked no later
than March 22, 2010. The conference calls will be held on Tuesday,
February 23, 2010 from 10 a.m. to 11:30 a.m.; Wednesday, February 24,
2010 from 2:30 p.m. to 4 p.m.; and Friday, March 5, 2010 from 1 p.m. to
2:30 p.m. All listed times are eastern standard times. Participants
must register for the conference calls by contacting Richard Laeng,
Public Health Analyst, at (301) 443-5410 or e-mail rlaeng@hrsa.gov. The
registration deadline is Thursday, February 18, 2010. Because the same
information will be discussed on all the calls, it is not necessary to
register for multiple calls. Registration is not guaranteed; it is on a
first come basis.
ADDRESSES: Please send all written comments to Mesmin Germain, Public
Health Analyst, Division of Transplantation, Healthcare Systems Bureau,
Health Resources and Services Administration, Department of Health and
Human Services, Room 12C-06, Parklawn Building, 5600 Fishers Lane,
Rockville, Maryland 20857; telephone: (301) 443-0053; fax: (301) 594-
6095; e-mail: mgermain@hrsa.gov.
FOR FURTHER INFORMATION CONTACT: Mesmin Germain, Public Health Analyst,
Division of Transplantation, Healthcare Systems Bureau, Health
Resources and Services Administration, Department of Health and Human
Services, Room 12C-06, Parklawn Building, 5600 Fishers Lane, Rockville,
Maryland 20857; telephone: (301) 443-0053; fax: (301) 594-6095; e-mail:
mgermain@hrsa.gov.
SUPPLEMENTARY INFORMATION:
Background
On September 14, 2006, HRSA awarded a 4-year cooperative agreement
to the Regents of the University of Michigan to establish a national
Program to provide reimbursement to living donors for travel and
subsistence expenses, as well as additional expenses authorized by any
future regulations issued by the Secretary. The Regents of the
University of Michigan in partnership with the American Society of
Transplant Surgeons (ASTS) established the National Living Donor
Assistance Center (NLDAC) to operate this national Program.
On October 17, 2007, The Regents of the University of Michigan and
ASTS officially launched NLDAC. NLDAC is located at the ASTS
Headquarter in Arlington, Virginia. NLDAC has officially partnered with
299 living transplant programs throughout the United States to submit
applications for reimbursement on behalf of their living donors.
Applications are filed through the transplant centers and reviewed by a
committee at NLDAC. Program eligibility is based on donor and recipient
incomes of 300 percent or less of the HHS Poverty Guidelines.
Applicants who do not meet eligibility guidelines may request a waiver.
All waiver requests are reviewed for approval by HRSA. The Program
provides prospective reimbursement to living donors based on the
estimated travel expenses related to the donation process. Funds are
provided through a controlled value card, giving NLDAC the ability to
add and subtract funds as needed. All expenses are monitored in real
time by NLDAC to ensure that donors are using funds according to
Program guidelines.
HRSA sought input from the public from the conceptual stage of the
Program through the determination of the Program's final eligibility
criteria to ensure that the Program addresses the needs of the public:
On October 13, 2005, HRSA published a Request for Public
Comments on the proposed Program to provide reimbursement of travel and
subsistence expenses in the Federal Register (70 FR 59760).
On April 9, 2007, HRSA published a Request for Public
Comments concerning the proposed Program eligibility criteria in the
Federal Register (72 FR 17564).
On October 5, 2007, HRSA published a Response to
Solicitation of Comments and Final Program Eligibility Guidelines in
the Federal Register (72 FR 57049).
On March 5, 2008, HRSA published a Request for Public
Comments on proposed changes to the reimbursement of travel and
subsistence expenses Program eligibility criteria (concerning
additional follow-up visits for donors) in the Federal Register (73 FR
11930).
On June 20, 2008, HRSA published a change to Program
eligibility guidelines to provide reimbursement for additional follow-
up visits for donors in the Federal Register (73 FR 35143).
On March 4, 2009, HRSA published a Request for Public
Comments on a proposed change to the Program eligibility criteria
(concerning the follow-up period) in the Federal Register (74 FR 9407).
On June 19, 2009, HRSA published an amendment to Program
eligibility guidelines to extend follow-up period that donors may
receive reimbursement for qualifying expenses in the Federal Register
(74 FR 29218).
Through September 30, 2009, the Program has facilitated 370 living
organ transplants. Overall, 697 applications have been approved for
funding under the established Program eligibility guidelines. The
average reimbursement per living donor is approximately $2,600.
HRSA initiated this Program to address the travel and subsistence
expenses faced by potential donors, recipients, and family alike. Even
with this support, living donors still face other financial barriers
related to the donation process.
Reimbursement of other incidental nonmedical expenses being
considered would further diminish the financial barriers faced by many
donors. Reimbursement for the additional expenses would be provided
while maintaining the existing Program guidelines, including capping
total reimbursement per donor and companions at $6,000. The expansion
will be provided under the Qualified
[[Page 875]]
Expenses Section of the Program Eligibility Guidelines.
Any payment permitted under this authority must not violate section
301 of the National Organ Transplant Act of 1984, which makes it
``unlawful for any person to knowingly acquire, receive, or otherwise
transfer any human organ for valuable consideration for use in human
transplantation if the transfer affects interstate commerce.'' 42
U.S.C. 274e(a). Certain expenses are excluded from the scope of
valuable consideration, including ``expenses of travel, housing, and
lost wages incurred by the donor of a human organ in connection with
the donation of the organ.'' 42 U.S.C. 274e(c)(2). As the Secretary
considers rulemaking, she will consider this criminal prohibition in
evaluating which expenses are appropriate for reimbursement under this
Program.
HRSA is seeking public comment as to whether the Secretary should
initiate rulemaking to allow reimbursement under this Program for
specific incidental nonmedical expenses and concerning which incidental
nonmedical expenses should be included in such rulemaking.
Dated: December 29, 2009.
Mary K. Wakefield,
Administrator.
[FR Doc. E9-31312 Filed 1-5-10; 8:45 am]
BILLING CODE 4165-15-P